Skip to content

Key resources

  • Bibliography
    Bibliography
  • Health promotion
    Health promotion
  • Health practice
    Health practice
  • Yarning places
    Yarning places
  • Programs
    Programs
  • Organisations
    Organisations
  • Conferences
    Conferences
  • Courses
    Courses
  • Funding
    Funding
  • Jobs
    Jobs
Australian Indigenous HealthBulletin
 

spacing1What is Hib?

hib banner

Introduction

The bacterium Haemophilus influenzae has been historically a common cause of infection in human populations. H. influenzae infections, while traditionally less common than many viral infections, cause a variety of childhood diseases, a number of which give rise to considerable morbidity and mortality [1].

H. influenzae type b (Hib) has in the past been responsible for a large proportion of the most serious forms of H. influenzae disease [2]. Hib disease is a significant cause of childhood hospitalisation and, although well known among paediatricians, is generally unfamiliar to the general public [3].

Hib infections are now preventable through vaccination. More than 90 countries world-wide use the vaccine as part of their immunisation schedules, which has led to the near eradication of Hib disease from many developed countries [4]. As more countries implement vaccination programs, non-type b H. influenzae, for which no vaccines are yet available, will be responsible for a growing proportion of H. influenzae infections.

Haemophilus influenzae type b

H. influenzae type b is a gram-negative bacterium found among the normal flora of the human respiratory tract [5]. Of the six types of H. influenzae identified (a to f), Hib is the most virulent [6]. Hib affects mainly young children, with 80% of cases worldwide occurring in children younger than five years of age [2]. Hib is spread by respiratory secretions. Consequently, contact with other children, either in large families or day care centres, has been identified as a principal risk factor for the development of Hib disease [7][8]. The risk posed by crowding is increased for children who are not breastfed [9].

Invasive Hib disease

Hib disease is considered to be ‘invasive' when it results in significant morbidity and mortality. The clinical manifestations of Hib include meningitis, epiglottitis, pneumonia, septicaemia, cellulitis, osteomyelitis, pericarditis and septic arthritis [2]. Meningitis and epiglottitis are considered the most serious forms of invasive Hib disease in Australia. Both cause significant morbidity and both are potentially fatal [8]. Meningitis is an infection of the meninges (outer tissue membranes) of the brain and spinal cord [10]. Treatment requires intensive care and antibiotic therapy [11]. Most cases will respond to administration of large doses of antibiotics, but approximately 10% of survivors suffer serious and permanent neurological impairment [12]. If subsequent learning deficits and behavioural problems are included among the sequelae, the proportion of survivors affected may rise as high as 40% [13]. Like meningitis, epiglottitis, an infection of the upper airways that causes obstruction [14], requires hospitalisation and intensive care. It too may be fatal, but mortality is generally rare, recovery is usually complete, and long-term sequelae are uncommon [15].

Before the introduction of Australia's national vaccination program, the various forms of invasive Hib disease represented a significant threat to the health and wellbeing of all Australian children. At that time, it was estimated that there were at least 500 cases of Hib in Australian children under the age of six [5], resulting in 10-15 deaths annually [3]. Approximately 5% of cases resulted in deaths, and up to 40% of the surviving patients had neurological sequelae, including deafness and intellectual impairment [11].

Australia launched its fully-funded infant Hib vaccine program in May 1993, with a catch-up immunization for children up to the age of 5 commencing in July 1993 [2]. Between 1993 and 2000, there were different vaccine schedules for Indigenous and non-Indigenous children.

Vaccination drastically reduced the incidence of Hib in both Indigenous and non-Indigenous children. In the seven year period between 1993 and 2000, notifications of Hib declined by 87%-95% among Australian children aged between 0-4 years of age [2].

Despite vaccinations being available to all children and a dramatic decrease in the overall incidence of Hib, Indigenous people continue to be at greater risk than non-Indigenous people, with rate ratios ranging from 2.7 (1993-1994) to 17.6 (2002-2003) . During 2004-2005, Indigenous people were 7.5 times more likely to be diagnosed with invasive Hib than non-Indigenous people (15 and 35 cases, respectively).

Almost 60% of Hib cases are preventable and are the result of children being either under or unimmunised . The proportion of these preventable cases was the same for Indigenous and non-Indigenous Australians.

References

  1. Hanna JN (2004) Impact of Haemophilus influenzae type b (Hib) vaccination on Hib meningitis in children in Far North Queensland, 1989 to 2003. Communicable Diseases Intelligence; 28(2): 255-257
  2. Horby P, Gilmour R, Wang H, McIntyre P (2003) Progress towards eliminating Hib in Australia: an evaluation of Haemophilus influenzae type b prevention in Australia, 1 July 1993 to 30 June 2000. Communicable Diseases Intelligence; 27(3): 324-341
  3. McIntyre P (1992) Invasive Haemophilus influenzae type b disease in Australia: the beginning of the end?. Medical Journal of Australia; 156: 516-518
  4. World Health Organization (2006) WHO position paper on Haemophilus influenzae type b conjugate vaccines. Weekly Epidemiological Record; 81(47): 445-452
  5. The Australian immunisation handbook (2008) National Health and Medical Research Council
  6. Heath PT, Booy R, Azzopardi HJ, Slack MPE, Fogarty J, Moloney AC, Ramsay ME, Moxon ER (2001) Non-type b Haemophilus influenzae disease: clinical and epidemiologic characteristics in the Haemophilus influenzae type b vaccine era. Pediatric Infectious Disease Journal; 20(3): 300-305
  7. Stubbs E, Hare K, Wilson C, Morris P, Leach AJ (2005) Streptococcus pneumoniae and noncapsular haemophilus influenzae nasal carriage and hand contamination in children: a comparison of two populations at risk of otitis media. Pediatric Infectious Disease Journal; 24(5): 423-428
  8. Gilbert GL (1992) New vaccines against Haemophilus influenzae type b. Modern Medicine; 35(6): 70-71
  9. Silfverdal SA, Ekholm L, Bodin L (2007) Breastfeeding enhances the antibody response to Hib and Pneumococcal serotype 6B and 14 after vaccination with conjugate vaccines. Vaccine; 25(8): 1497-1502
  10. Meningitis (2009) Better Health Channel
  11. Moxon ER (1991) International conference on prevention of Hib meningitis in the 1990's. Vaccine; 9(Suppl. June): S4
  12. Gilbert GL (1992) New vaccines for Haemophilus influenzae type b disease. Medical Journal of Australia; 156(Apr 20): 518-520
  13. Haemophilus influenzae type b (Hib) (2008) Better Health Channel
  14. Bower C (1993) HIB vaccination programs: an example of the nexus between epidemiology and equity in health promotion. Health Promotion Journal of Australia; 3(2): 44-45
  15. Wang H, Deeks S, Glasswell A, McIntyre P (2008) Trends in invasive Haemophilus influenzae type b disease in Australia, 1995-2005. Communicable Diseases Intelligence; 32(3): 316-325

© Australian Indigenous HealthInfoNet 2013 
This product, excluding the Australian Indigenous HealthInfoNet logo, artwork, and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY-NC-ND 3.0 (CC BY-NC-ND 3.0) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures.

 

Table of Contents

a
collapseCollapse
expand Expand
    Last updated: 30 July 2009
     
    Return to top
    spacing
    general box

    Contribute

    Share your information » Give us feedback » Sign our guestbook »
    spacing
    spacing